OATP polymorphism

Tirona, R. G., Leake, B. F., Merino, G., Kim, R. B., Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European-and African-Americans, J. Bid. Chem. 2001, 276, 35669-35675. 

Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J., Sai, Y., Tsuji, A., Yokoi, T., Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9) allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther. 2002, 302, 804-813. 

M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, and Y. Sugiyama. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14 749-757 (2004). 

Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., and Tamai, 1. (2005) Role of organic anion transporter OATPIBI (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33, 434—439. 

Niemi, M., Schaeffeler, E., Lang, T., et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCOIBI). Pharmacogenetics. 14, 429-440. 

Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., et al. (2004) Effect of genetic polymorphism of OATP-C (SLCOIBI) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380. 

Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003 73 554—565. 

---